Biotech Values

[RockRat]

>>Under your scenario, MNTA’s expertise would no longer be available to facilitate FDA approval of the Copaxone ANDA.<<

Some of the know how and IP would have to go with it. Even with Momenta shepherding the ANDA all the way, it is by no means a given that the ANDA will be approved. The tough question is what price tag to put on it, since some the IP and expertise that goes with it could be used in other ways. It would be a difficult deal, and I agree the whole concept is unlikely, but I could see some attractiveness in it for Teva.

Whatever, the odds of a takeout are higher with other players. I'll leave it at that.

Regards, RockRat